Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevanimibe Dose-Titration in Classic CAH
NCT03669549Phase 2Terminated
- Sponsor
- Millendo Therapeutics
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of Nevanimibe in congenital adrenal hyperplasia (CAH), sponsored by Millendo Therapeutics. Primary endpoint: Percentage of Subjects Achieving Serum 17-OHP Targets at Day 113. Started Jul 2018; status: terminated.
02
Drugs
Nevanimibe
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT03669549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669549.